| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;42:749.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
From The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine (K.B.B., L.A.A.N., J.J., D.B.A., M.C.C., C.M.F.), Winston-Salem, NC; and the Departments of Medical Biophysics and Immunology, Amgen Research Institute/Ontario Cancer Institute (R.S., J.P.), Toronto, Ontario, Canada.
Correspondence to K. Bridget Brosnihan, PhD, The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1032. E-mail bbrosnih{at}wfubmc.edu
| Abstract |
|---|
|
|
|---|
Key Words: angiotensin renin-angiotensin system pregnancy kidney angiotensin-converting enzyme 2
| Introduction |
|---|
|
|
|---|
The profile of peptides in the kidney with increased content of Ang-(1-7) without a buildup in the levels of Ang II is consistent with an enzymatic pathway of a recently described enzyme of the RAS, ACE2. ACE2 is a carboxypeptidase that converts Ang I into Ang-(19), but it also exhibits high catalytic efficiency to generate Ang-(1-7) from Ang II.1012 The ACE2 catalytic activity for Ang II as compared with Ang I is 400-fold higher, making Ang II a central player in the metabolic pathway for the formation of Ang-(1-7). Chappell et al13 provided the first direct evidence for the presence of ACE2 staining in the renal tubular system of the rat. The high kidney concentrations of Ang-(1-7) during pregnancy raised the question of whether ACE2 may be localized in association with Ang-(1-7) in the kidney such that it could account for the increased production of Ang-(1-7). In these studies, we sought to determine if pregnancy changed the intensity or distribution of immunocytochemical (ICC) staining of Ang-(1-7) and ACE2 in the kidney.
| Experimental Procedures |
|---|
|
|
|---|
Surgical Procedure
At the 19th day of pregnancy or an equivalent age in virgin female rats, the animals were killed by decapitation. The 19th day of pregnancy was selected in accordance with our previous publication describing the kidney content and urinary excretion of angiotensin peptides.1 The kidneys were rapidly removed and immediately placed in a solution of 4% formalin acetate or frozen on dry ice. Frozen tissues were transferred to a -80°C freezer until processed.
Immunocytochemistry
Tissues were left in fixative for 24 to 48 hours before being transferred to 70% ethanol. Kidney tissues were then imbedded in paraffin, and 5-µm sections were obtained. Immunocytochemistry distribution of Ang-(1-7) and ACE2 were obtained through the use of the avidin-biotin method as previously published.14 All tissues from pregnant and virgin rats were prepared and analyzed in paired sections. The primary antibodies used were an affinity-purified rabbit polyclonal antibody to Ang-(1-7) produced by our laboratory at a dilution of 1:25 in 1% BSA and a mouse monoclonal antibody to ACE2 diluted 1:300 in 1% BSA provided by J. Penninger. Ang-(1-7) antibody purification and characterization have been described previously.15 The secondary antibody used was biotinylated goat anti-rabbit for Ang-(1-7) staining or biotinylated horse anti-mouse for ACE2 staining (Vector Laboratories), diluted 1:400 in 1% BSA. Sections were stained brown with 3,3'-diaminobenzidine (DAB, Sigma Chemical Co) in Tris-buffered saline (0.05 mol/L, pH 7.6 to 7.7) and counterstained with hematoxylin before being dehydrated and mounted. Some sections were not counterstained with hematoxylin and were used for quantitative analysis. To validate the staining procedure, kidney sections were incubated with the secondary antibody alone without the primary antibody. In addition, the specificity of the staining obtained with the Ang-(1-7) antibody was assessed by preabsorption of the antibody with 10 µmol/L Ang-(1-7) (Bachem). The specificity of the Ang-(1-7) antibody for ICC has been previously described.16,17 Briefly, it does not cross-react with Ang I or Ang II. The peptide sequence used to make the ACE2 antibody is unique to ACE2 but not ACE or the ACE2 homologue collectrin18; in Western blotting, the antibody recognizes only two bands in the renal cortex at 89 and 125 kDa that correlate with the nonglycosylated and glycosylated forms of ACE2.
Quantification of Immunocytochemical Staining
The Ang-(1-7) and ACE2 staining was quantified as previously published.19 The digitization of images was performed with a Zeiss microscope equipped with an AxioCam digital camera that transmits the image data to the AxioVision software (Zeiss). All images were obtained with the use of a x20 objective. Three x20 fields of the inner cortex/outer medulla region containing at least one glomerulus were chosen from each animal to best reflect the overall immunostaining contained on the entire section. For the entire study, the image intensity was kept at an identical level. The corrected quantitative intensity was calculated as the difference between intensity of the immunostaining in tubules versus glomeruli (background). The results were averaged from 4 to 5 rats in each group.
Statistical Analysis
Comparisons between the groups were performed with the use of a 2-tailed, unpaired Student t test (GraphPad Software). A probability value of <0.05 was considered statistically significant. All values are presented as mean±SEM.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
The renal distribution of Ang-(1-7) shown in virgin and pregnant rats is in agreement with previous studies by Ferrario et al,14 who provided the first direct evidence for the presence of Ang-(1-7) staining in the renal tubular system of the rat. The renal distribution of Ang-(1-7) immunostaining is in accordance with functional studies, which demonstrated that Ang-(1-7) has an important role in renal homeostasis.20 At the level of the proximal tubules, Ang-(1-7) has a potential role in regulating sodium transport7,8,21 by modulating renal Na+/K+-ATPase activity and reducing energy-dependent transcellular Na+ transport. Ang-(1-7) has also been shown to elicit potent diuretic effects associated with increased prostaglandin production.7,22,23 Ang-(1-7) also has been shown to increase glomerular filtration rate.21 Most of the renal actions of Ang-(1-7) are opposite to those of Ang II. In this regard, Ang-(1-7) was shown to dilate renal afferent arterioles through nitric oxide release.24 The direct effect of Ang-(1-7) in renal function during pregnancy has not been determined; however, pregnancy does increase the vasodilator response of Ang-(1-7) in mesenteric resistance vessels,1 a finding consistent with its counterbalancing the actions of Ang II.
The increased ICC expression of Ang-(1-7) during late pregnancy is in agreement with our previous study showing increased kidney concentration of Ang-(1-7).1 In pregnancy, the kidney ratio of Ang-(1-7)/Ang II increased to 2.48±0.97, as compared with 0.89±0.36 in the virgin rats. These ratios have been used to provide evidence of enzymatic conversion of angiotensins, and the pattern observed in pregnancy is consistent with an efficient conversion of Ang II to Ang-(1-7). ACE2, which has only recently been recognized to be a participant in the RAS, is a metalloproteinase with carboxypeptidase properties that participates in the formation of Ang-(1-7) from Ang II or Ang I. The catalytic efficiency of ACE2 for generating Ang-(1-7) from Ang II is almost 400-fold greater than that for the conversion of Ang I to Ang-(19) and 10- to 600-fold higher than that of two other Ang-(1-7) forming enzymes, prolyl oligopeptidase and prolylcarboxypeptidase, respectively.11 ACE2 appeared to be colocalized with Ang-(1-7) in the tubules of the inner cortex and outer medulla, and its increased ICC expression in the kidneys of pregnant rats would suggest that ACE2 is a primary candidate for Ang-(1-7) formation.
Our previous findings of increased kidney levels of Ang-(1-7) with increased urinary excretion of Ang-(1-7) without a change in circulating levels of Ang-(1-7) during pregnancy is important because it supports the local renal production of Ang-(1-7). In pregnancy, the percent increase in the urinary excretion rates of Ang I (93%) and Ang-(1-7) (60%) were greater than the increase in urine flow (46%) in the virgin rats, suggesting that there is active secretion of Ang I and Ang-(1-7) from the kidney that is greater than the diuresis associated with pregnancy. Since plasma levels of the peptides were unchanged at this stage of pregnancy (19th day), the increase is unlikely to be due to uptake from the circulation. The site of Ang-(1-7) production in the kidney has not been characterized. To assess this, it will be important to determine the kidney localization of Ang II in association with ACE2. Ang II staining has been localized to juxtaglomerular cells and proximal tubules.25 In addition to an intracellular localization within the kidney,25,26 Ang II has been shown to be in tubular fluid,27 interstitial fluid compartments, and urine,1,28 making it available as a substrate for either intracellular or tubular formation of Ang-(1-7). Because ACE2 has been shown to be present in the urine in addition to the tubular location described in these studies (unpublished data from Dr Mark Chappell, 2003), it is likely that it also can be secreted. Thus both renal intracellular and interstitial formation of Ang-(1-7) may occur. Future studies are required to address this issue.
Other enzymes that have been demonstrated to participate in the formation of Ang-(1-7) include neprilysin and thimet oligopeptidase, with the contribution of each enzyme dependent on tissue source and vascular compartment. In the kidney, neprilysin has been shown to be a major contributor to Ang-(1-7) formation.20 However, we have shown previously that renal neprilysin activity is not changed with estrogen replacement,29 making it unlikely to be responsible for the increase in Ang-(1-7) formation because of the increase in estrogen that occurs in pregnancy. On the other hand, ACE has also been shown to participate in the metabolism of Ang-(1-7) by metabolizing Ang-(19) or by degrading Ang-(1-7) to inactive metabolites.30,31 Since we have previously shown that estrogen downregulates ACE activity and mRNA expression in kidney cortex and medulla and that serum ACE is reduced in pregnancy,32 the contribution of ACE to the elevated Ang-(1-7) levels with pregnancy is a likely possibility, more by preventing its degradation than enhancing its formation. Although our study provides evidence that indicates that ACE2 may play a critical role on the Ang-(1-7) formation, in vivo studies evaluating the participation of the different metabolic pathways for Ang-(1-7) formation during pregnancy need to be investigated.
The present study is the first demonstration of the immunocytochemical distribution of Ang-(1-7) and its processing enzyme ACE2 in the kidney of pregnant rats. The increased ACE2 intensity in association with an increased Ang-(1-7) immunostaining in pregnancy suggests that ACE2 may act to contribute to the overexpression of Ang-(1-7) in the kidney during pregnancy and shift the Ang II/Ang-(1-7) balance away from Ang II.
Perspectives
Recent studies by Crackower et al18 on ACE2 expression and blood pressure regulation, taken together with the information available on the Ang-(1-7) vasodilator and blood pressurelowering effects, suggest that ACE2 may play a critical role in blood pressure regulation by modulating the balance of the vasoconstrictor and vasodilator components of the RAS. The present study indicates that ACE2 may contribute to a shift in the Ang II/Ang-(1-7) balance during pregnancy by contributing to increased Ang-(1-7) formation. Because pregnancy is a physiological condition, where there is an activation of the RAS but blood pressure is normal or decreased, the enhanced expression of Ang-(1-7) may play a critical role in the maintenance of blood pressure. Critical areas for further investigation concern the identification of the role ACE2 plays in Ang-(1-7) formation in vivo in late pregnancy, as well as assessing ACE2 expression in reproductive organs during pregnancy. More important will be the evaluation of ACE2 expression and its role in Ang-(1-7) formation during preeclampsia.
| Acknowledgments |
|---|
Received May 5, 2003; first decision May 21, 2003; accepted June 25, 2003.
| References |
|---|
|
|
|---|
2. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993; 234: 3542.[CrossRef][Medline] [Order article via Infotrieve]
3. Oliveira MA, Fortes ZB, Santos RA, Kosla MC, DeCarvalho MH. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides. 1999; 20: 11951201.[CrossRef][Medline] [Order article via Infotrieve]
4. Forster C, le Tran Y. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol. 1997; 30: 676682.[CrossRef][Medline] [Order article via Infotrieve]
5. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996; 27: 523528.
6. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 1996; 28: 104108.
7. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7) in vivo and in vitro studies. Am J Physiol. 1996; 270: F141F147.[Medline] [Order article via Infotrieve]
8. Andreatta-Van Leyen S, Romero MF, Khosla MC, Douglas JG. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). Kidney Int. 1993; 44: 932936.[Medline] [Order article via Infotrieve]
9. Chappell MC. Evidence for the formation of angiotensin-(1-7) and the inhibitory actions of the peptide on Na+,K+-ATPase activity in rat proximal tubules. Hypertension. 2001; 38: 523.Abstract.
10. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme: cloning and functional expression of a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275: 3323833243.
11. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277: 1483814843.
12. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robinson K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87: e1e9.[Medline] [Order article via Infotrieve]
13. Chappell MC, Jung F, Gallagher PE, Averill DB, Crackower MA, Penninger JM, Ferrario CM. Omapatrilat treatment is associated with increased ACE-2 and angiotensin-(1-7) in spontaneously hypertensive rats. Hypertension. 2002; 40: 409.Abstract.
14. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int. 2002; 62: 13491357.[CrossRef][Medline] [Order article via Infotrieve]
15. Moriguchi A, Tallant EA, Matsumura K, Reilly TM, Walton H, Ganten D, Ferrario CM. Opposing actions of Angiotensin-(1-7) and Angiotensin II in the brain of transgenic hypertensive rats. Hypertension. 1995; 25: 12601265.
16. Krob HA, Vinsant SL, Ferrario CM, Friedman DP. Angiotensin-(1-7) immunoreactivity in the hypothalamus of the (mRen-2d)27 transgenic rat. Brain Res. 1998; 798: 3645.[CrossRef][Medline] [Order article via Infotrieve]
17. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation. 2003. In press.
18. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santo AJ, da Costa J, Zhang L, Pei Y, Scholey J, Bray MR, Ferrario CM, Backx PH, Manoukian AS, Chappell MC, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417: 822828.[CrossRef][Medline] [Order article via Infotrieve]
19. Lehr H-A, Mankoff DA, Corwin D, Santeusanio G, Gown A. Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 1997; 45: 15591565.
20. Chappell MC, Iyer SN, Diz DI, Ferrario CM. Antihypertensive effects of angiotensin-(1-7). Braz J Med Biol Res. 1998; 31: 12051212.[Medline] [Order article via Infotrieve]
21. Heller J, Kramer HJ, Maly J, Cervenka L, Horacek V. Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res. 2000; 23: 8994.[CrossRef][Medline] [Order article via Infotrieve]
22. Heyne N, Beer W, Muhlbauer B, Osswald H. Renal response to angiotensin (1-7) in anesthetized rats. Kidney Int. 1995; 47: 975976.
23. DelliPizzi A, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin (1-7). Br J Pharmacol. 1994; 111: 13.[Medline] [Order article via Infotrieve]
24. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002; 39: 799802.
25. Inagami T, Kawamura K, Naruse K, Okamura T. Localization of components of the renin-angiotensin system within the kidney. Fed Proc. 1986; 45: 14141419.[Medline] [Order article via Infotrieve]
26. Mercure C, Ramla D, Garcia R, Thibault G, Deschepper CF, Reudelhuber TL. Evidence for intracellular generation of angiotensin II in rat juxtaglomerular cells. FEBS Lett. 1998; 422: 395399.[CrossRef][Medline] [Order article via Infotrieve]
27. Nishiyama A, Kimura S, Fukui T, Rahman M, Yoneyama H, Kosaka H, Abe Y. Blood flow-dependent changes in renal interstitial guanosine 3', 5'-cyclic monophosphate in rabbits. Am J Physiol Renal Physiol. 2002; 282: F238F244.
28. Valdes G, Germain AM, Corthorn J, Berrios C, Foradori AC, Ferrario CM, Brosnihan KB. Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine. 2001; 16: 117122.[CrossRef][Medline] [Order article via Infotrieve]
29. Neves LA, Chappell MC, Ferrario CM, Brosnihan KB. Effect of estrogen replacement on neprilysin activity in kidney of [mREN-2]27 transgenic hypertensive and normotensive rats. FASEB J. 2001; 15; A779.
30. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties, and enzymatic activity of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 1993; 52: 14611480.[CrossRef][Medline] [Order article via Infotrieve]
31. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. Hypertension. 1998; 31: 362367.
32. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension. 1999; 33: 323328.
This article has been cited by other articles:
![]() |
E. Gava, A. Samad-Zadeh, J. Zimpelmann, N. Bahramifarid, G. T. Kitten, R. A. Santos, R. M. Touyz, and K. D. Burns Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1766 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Y. Oudit, Y. Imai, K. Kuba, J. W. Scholey, and J. M. Penninger The role of ACE2 in pulmonary diseases--relevance for the nephrologist Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1362 - 1365. [Full Text] [PDF] |
||||
![]() |
A. Levy, Y. Yagil, M. Bursztyn, R. Barkalifa, S. Scharf, and C. Yagil ACE2 expression and activity are enhanced during pregnancy Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1953 - R1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Anton and K. B. Brosnihan Review: Systemic and uteroplacental renin--angiotensin system in normal and pre-eclamptic pregnancies Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 349 - 362. [Abstract] [PDF] |
||||
![]() |
A. K. Sampson, K. M. Moritz, E. S. Jones, R. L. Flower, R. E. Widdop, and K. M. Denton Enhanced Angiotensin II Type 2 Receptor Mechanisms Mediate Decreases in Arterial Pressure Attributable to Chronic Low-Dose Angiotensin II in Female Rats Hypertension, October 1, 2008; 52(4): 666 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Ferrario, K. B. Brosnihan, and M. C. Chappell Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H10 - H20. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Soler, J. Wysocki, and D. Batlle Angiotensin-converting enzyme 2 and the kidney Exp Physiol, May 1, 2008; 93(5): 549 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ji, S. Menini, W. Zheng, C. Pesce, X. Wu, and K. Sandberg Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17{beta}-oestradiol regulation of renal pathology in renal wrap hypertension in rats Exp Physiol, May 1, 2008; 93(5): 648 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Sullivan Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1220 - R1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. A. Neves, K. Stovall, J. Joyner, G. Valdes, P. E. Gallagher, C. M. Ferrario, D. C. Merrill, and K. B. Brosnihan ACE2 and ANG-(1-7) in the rat uterus during early and late gestation Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R151 - R161. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. B. Ojeda, D. Grigore, E. B. Robertson, and B. T. Alexander Estrogen Protects Against Increased Blood Pressure in Postpubertal Female Growth Restricted Offspring Hypertension, October 1, 2007; 50(4): 679 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Joyner, L. A. A. Neves, J. P. Granger, B. T. Alexander, D. C. Merrill, M. C. Chappell, C. M. Ferrario, W. P. Davis, and K. B. Brosnihan Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R169 - R177. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Stepan, R. Faber, N. Dornhofer, B. Huppertz, A. Robitzki, and T. Walther New Insights into the Biology of Preeclampsia Biol Reprod, May 1, 2006; 74(5): 772 - 776. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Danilczyk and J. M. Penninger Angiotensin-Converting Enzyme II in the Heart and the Kidney Circ. Res., March 3, 2006; 98(4): 463 - 471. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ferrario, A. J. Trask, and J. A. Jessup Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Warner, R. A. Lew, A. I. Smith, D. W. Lambert, N. M. Hooper, and A. J. Turner Angiotensin-converting Enzyme 2 (ACE2), But Not ACE, Is Preferentially Localized to the Apical Surface of Polarized Kidney Cells J. Biol. Chem., November 25, 2005; 280(47): 39353 - 39362. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Riviere, A. Michaud, C. Breton, G. VanCamp, C. Laborie, M. Enache, J. Lesage, S. Deloof, P. Corvol, and D. Vieau Angiotensin-Converting Enzyme 2 (ACE2) and ACE Activities Display Tissue-Specific Sensitivity to Undernutrition-Programmed Hypertension in the Adult Rat Hypertension, November 1, 2005; 46(5): 1169 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Lambert, M. Yarski, F. J. Warner, P. Thornhill, E. T. Parkin, A. I. Smith, N. M. Hooper, and A. J. Turner Tumor Necrosis Factor-{alpha} Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2) J. Biol. Chem., August 26, 2005; 280(34): 30113 - 30119. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ferrario, J. Jessup, M. C. Chappell, D. B. Averill, K. B. Brosnihan, E. A. Tallant, D. I. Diz, and P. E. Gallagher Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 Circulation, May 24, 2005; 111(20): 2605 - 2610. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, J. Zimpelmann, K. Cheng, J. A. Wilkins, and K. D. Burns The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules Am J Physiol Renal Physiol, February 1, 2005; 288(2): F353 - F362. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Zhong, D.-Y. Huang, Y.-M. Yang, Y.-F. Li, G.-F. Liu, X.-H. Song, and K. Du Upregulation of Angiotensin-Converting Enzyme 2 by All-trans Retinoic Acid in Spontaneously Hypertensive Rats Hypertension, December 1, 2004; 44(6): 907 - 912. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |